N2OFF's 15min chart triggers KDJ Golden Cross, Bullish Marubozu formation.

The 15-minute chart for N2OFF has recently displayed a significant bullish indicator, with a golden cross of the KDJ indicator and a bullish marubozu candlestick pattern on October 3, 2023 at 11:45. This suggests that the momentum of the stock price is shifting in favor of an upward trend, potentially leading to further gains. The dominance of buyers in the market and the ongoing bullish momentum indicate a strong likelihood of continued upward movement.

N2OFF Inc. (NASDAQ: NITO) shares surged on Tuesday following the approval of a key acquisition by shareholders at a special meeting on September 25, 2025. The approval of the acquisition of SciSparc Ltd.'s (NASDAQ: SPRC) majority-owned subsidiary, MitoCareX Bio Ltd., marks a significant milestone towards completing the deal SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition^[1].

The acquisition agreement, announced on February 25, 2025, involves N2OFF purchasing 6,622 shares of MitoCareX for $700,000 and exchanging the remaining outstanding shares for 40% of N2OFF's fully diluted capital stock. The sellers, including SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri, will receive 30% of N2OFF's financing proceeds (capped at $1.6 million) over five years and potential additional stock issuances of up to 25% of N2OFF common stock SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[2].

MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 protein family. The global cancer therapeutics and biotherapeutics market was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031 SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[2].

N2OFF has committed to financially supporting MitoCareX's operations during the first two years post-closing, including an initial $1 million cash investment. The transaction is expected to close in the first half of October 2025, pending satisfaction of remaining conditions SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition^[1].

The approval by N2OFF shareholders represents a crucial step towards completing the acquisition, positioning N2OFF to enter the lucrative oncology market while providing SciSparc with both immediate cash consideration and significant long-term upside potential SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[2].